Townsend & Associates’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$223K Buy
8,993
+4
+0% +$105 0.02% 109
2026
Q1
$241K Buy
8,989
+3
+0% +$80 0.02% 108
2025
Q4
$233K Buy
8,986
+202
+2% +$5.09K 0.02% 105
2025
Q3
$215K Sell
8,784
-87
-1% -$2.15K 0.02% 107
2025
Q2
$220K Sell
8,871
-1,001
-10% -$23.3K 0.02% 99
2025
Q1
$218K Sell
9,872
-338
-3% -$8.85K 0.02% 94
2024
Q4
$272K Hold
10,210
0.03% 94
2024
Q3
$295K Buy
10,210
+404
+4% +$11.8K 0.03% 89
2024
Q2
$302K Buy
9,806
+6
+0.1% +$165 0.03% 87
2024
Q1
$258K Buy
9,800
+5
+0.1% +$139 0.03% 88
2023
Q4
$277K Sell
9,795
-209
-2% -$6.32K 0.03% 89
2023
Q3
$301K Sell
10,004
-10,092
-50% -$357K 0.06% 86
2023
Q2
$745K Sell
20,096
-396
-2% -$15.4K 0.19% 85
2023
Q1
$797K Sell
20,492
-27,261
-57% -$1.18M 0.32% 78
2022
Q4
$2.1M Sell
47,753
-457
-0.9% -$21.9K 1.04% 36
2022
Q3
$2.28M Buy
48,210
+6,685
+16% +$325K 1.05% 31
2022
Q2
$2.2M Buy
+41,525
New +$2.12M 1.02% 25
2021
Q1
Sell
-36,128
Closed -$1.33M 84
2020
Q4
$1.33M Sell
36,128
-4,362
-11% -$160K 0.97% 52
2020
Q3
$1.41M Sell
40,490
-13,026
-24% -$457K 1.11% 46
2020
Q2
$1.66M Sell
53,516
-6,642
-11% -$226K 1.39% 29
2020
Q1
$1.92M Buy
60,158
+166
+0.3% +$5.66K 1.99% 10
2019
Q4
$2.22M Sell
59,992
-2,510
-4% -$89.4K 1.94% 10
2019
Q3
$2.1M Buy
62,502
+12,919
+26% +$470K 2.01% 11
2019
Q2
$2.09M Buy
49,583
+301
+0.6% +$12K 1.59% 19
2019
Q1
$1.99M Buy
+49,282
New +$1.97M 2% 21
2018
Q4
Sell
-284
Closed -$12K 126
2018
Q3
$12K Buy
284
+3
+1% +$115 0.01% 129
2018
Q2
$10K Sell
281
-131
-32% -$4.48K 0.01% 129
2018
Q1
$14K Sell
412
-44,059
-99% -$1.51M 0.01% 124
2017
Q4
$1.53M Buy
+44,471
New +$1.52M 1.3% 27

Other funds holding PFE

Townsend & Associates's PFE Position: Q2 2026 in Review

Townsend & Associates increased its Pfizer (PFE) stake by 0.04% in Q2 2026, buying an estimated $105 and bringing the position to 8,993 shares worth $223K. The position accounts for 0.02% of the portfolio, ranked #109.

Townsend & Associates first reported a position in PFE in Q4 2017 and has held it in 29 quarters since. The position peaked at $2.28M in Q3 2022. 1,338 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Townsend & Associates held 8,993 shares of Pfizer worth $223K as of Q2 2026.
  • Townsend & Associates bought 4 Pfizer shares in Q2 2026, an estimated $105.
  • Pfizer made up 0.02% of Townsend & Associates's portfolio in Q2 2026, its #109 holding.
  • Townsend & Associates first reported a position in Pfizer in Q4 2017 and has held it in 29 quarters since.
  • Townsend & Associates's Pfizer position peaked at $2.28M in Q3 2022.
  • 1,338 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Townsend & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.